Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial
Erratum

Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

Fengrui Xu1,2, Yang Zhang3, Zhanhui Miao4, Xiaohua Zeng5, Biao Wu6, Li Cai7, Jinping Liu8, Shusen Wang9, Xichun Hu10, Wenbo Zheng11, Zhiyue Chen12, Qing Yang12, Zefei Jiang1

1Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China;2Department of Breast Oncology, Academy of Military Medical Sciences, Beijing 100089, China;3Department of Breast Surgery, Liaocheng People’s Hospital, Liaocheng 252000, China;4Department of Medical Oncology, The First Affiliated Hospital of Xinxiang University, Xinxiang 453100, China;5Department of Breast Surgery, Hongqing Cancer Hospital, Chongqing 400030, China;6Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China;7Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China;8Department of Breast Surgery, Sichuan Province People’s Hospital, Chengdu 610072, China;9Department of Medical Oncology, Zhongshan University Cancer Center, Guangzhou 510060, China;10Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China;11Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China;12Department of Research and Development, Jiangsu Hengrui Medicine Co., Ltd., Shanghai 200120, China

Correspondence to: Zefei Jiang. Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No. 8 East Street, Fengtai District, Beijing 100071, China. Email: jiangzefei@csco.org.cn.

doi: 10.21037/atm-2020-23

Erratum to: Ann Transl Med 2019;7:482.

Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial

In the article entitled “Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial” (1), the affiliation of Fengrui Xu should be corrected as follows: 1Department of Breast Oncology, Academy of Military Medical Sciences, Beijing 100089, China; 2Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China

We regret the errors.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

  1. Xu F, Zhang Y, Miao Z, et al. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med 2019;7:482. [Crossref] [PubMed]
Cite this article as: Xu F, Zhang Y, Miao Z, Zeng X, Wu B, Cai L, Liu J, Wang S, Hu X, Zheng W, Chen Z, Yang Q, Jiang Z. Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med 2020;8(10):660. doi: 10.21037/atm-2020-23

Article Options

Download Citation

Share